Are the side effects of zotuximab/veluoyi obvious?

Zolbetuximab (zolbetuximab)-Vyloy is a new type of targeted monoclonal antibody drug, and its side effects have been clearly recorded in clinical trials and post-marketing use. From the overall situation, adverse reactions of drugs do exist, but compared with traditional chemotherapy, the toxicity spectrum is more controllable, and most patients can be managed through dose adjustment and symptomatic treatment under the guidance of doctors.

In the published overseas clinical study results, the most common adverse reactions include nausea, vomiting, loss of appetite, diarrhea and fatigue. These symptoms are related to the mechanism of drug action, because CLDN18.2 is not only expressed in tumor tissue, but also exists to a certain extent on some normal gastric mucosal cells, so the gastrointestinal reaction is more prominent. In addition, some patients may experience infusion-related reactions, such as chills, fever, rash or blood pressure fluctuations. Such adverse reactions are usually more common during the first or early administration, and will gradually lessen as the number of subsequent administrations increases.

In terms of safety management, doctors will prescribe antiemetics or anti-allergic drugs in advance to reduce the probability of related side effects. It is worth noting that zolbetuximab has not yet been found to cause severe bone marrow suppression or widespread immunosuppression, which is significantly different from traditional chemotherapy drugs. Therefore, the drug is generally well tolerated, and the risks and benefits are acceptable in clinical use.

To sum up, the side effects of zotuximab/Veloyi are relatively clear, but most of them are mild to moderate and controllable, which will not offset its value in the precision treatment of gastric cancer. Patients need to follow up closely during the medication period and maintain communication with their doctors in order to effectively manage side effects while ensuring efficacy.

Reference materials:https://www.astellas.com/en/news/29401